Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR)
Launched by ASSOCIAÇÃO PARA O DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARV · Aug 11, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR) trial is studying how a personalized exercise program can help people who are recovering from a heart attack and also have knee osteoarthritis (KOA). The goal is to see if this tailored approach can reduce pain and improve mobility for individuals aged 50 and older who experience knee pain and have a history of heart issues. This study is important because there is little research on how exercise can specifically help this group of patients, who often face both joint pain and cardiovascular risks.
To qualify for the trial, participants must be at least 50 years old, have knee pain, and have experienced a heart attack with specific heart-related test results. They should also be able to walk independently. If you join the study, you can expect to engage in a structured exercise program designed just for you, aiming to enhance your quality of life by managing pain and improving physical function. It’s a great opportunity to adopt a healthier lifestyle while contributing to important research that could benefit others in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 50 or older; Knee pain, Morning stiffness that lasts no longer than 30 minutes and one of the following: crepitus, restricted function, bony enlargement. Acute Myocardial Infarction with myocardial lesion detected by abnormal cardiac biomarkers evidencing acute myocardial ischemia; High risk level in the Systematic Coronary Risk Evaluation (SCORE2) or the Systematic Coronary Risk Evaluation Older Person (SCORE2 O.P.) cardiovascular risk algorithm or prior cardiovascular disease; Independent gait
- Exclusion Criteria:
- • Occurrence of acute myocardial infarction with less than 12 months; Cognitive impairment- Montreal Cognitive Assessment (MoCA); Type 1 diabetes or insulin dependence; Pacemaker device; Knee prosthesis; Currently doing formal exercise session for more that 30 minutes per week; Class III or IV angina according to Canadian Cardiovascular Society criteria; Class III or IV symptoms according to New York Heart Association criteria; Type 2 Myocardial Infarction; Uncontrolled and symptomatic cardiac arrythmia with hemodynamic impact; Severe and symptomatic aortic valve stenosis; Uncontrolled and symptomatic heart failure; Active myocarditis, pericarditis or endocarditis; Acute aortic syndrome; Known or suspected desiccant aneurism; Acute systemic infection.
About Associação Para O Desenvolvimento Do Centro Académico De Investigação E Formação Biomédica Do Algarv
The Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarve (AD-CIFB) is a prominent clinical trial sponsor dedicated to advancing biomedical research and education in the Algarve region. By fostering collaboration among academic institutions, healthcare providers, and industry partners, AD-CIFB aims to enhance the quality and impact of clinical trials. The organization is committed to promoting innovative therapeutic solutions and improving patient outcomes through rigorous scientific inquiry and comprehensive training programs in biomedical sciences.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Faro, Algarve, Portugal
Patients applied
Trial Officials
Sandra R Pais, PhD
Principal Investigator
AD-ABC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported